Early Vedolizumab Trough Levels at Induction in Inflammatory Bowel Disease Patients With Treatment Failure During Maintenance

European Journal of Gastroenterology and Hepatology - United States
doi 10.1097/meg.0000000000001356
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Early Vedolizumab Trough Levels Predict Mucosal Healing in Inflammatory Bowel Disease: A Multicentre Prospective Observational Study

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Letter: Vedolizumab Drug Levels in Cord and Maternal Blood in Women With Inflammatory Bowel Disease-Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease

Clinical Therapeutics
Pharmacology
2018English

Rapid Response to Vedolizumab Therapy in Biologic-Naïve Patients With Inflammatory Bowel Diseases

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2019English

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

Digestive Diseases and Sciences
PhysiologyGastroenterology
2018English

Vedolizumab Exposure in Pregnancy: Outcomes From Clinical Studies in Inflammatory Bowel Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Letter: Vedolizumab for Autoimmune Liver Disease Associated Inflammatory Bowel Disease-Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

P095 Inflammatory Bowel Disease, During Anti IL 17 Treatment

2019English

Pain Management in Patients With Inflammatory Bowel Disease

Inflammatory Bowel Diseases
AllergyImmunologyGastroenterology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy